Prolonged survival of patients with EGFR-mutated non-small cell lung cancer with solitary brain metastases treated with surgical resection of brain and lung lesions followed by EGFR TKIs.
Prolonged survival of patients with EGFR-mutated non-small cell lung cancer with solitary brain metastases treated with surgical resection of brain and lung lesions followed by EGFR TKIs.
复制标题
EGFR 突变非小细胞肺癌伴孤立性脑转移患者接受脑部和肺部病灶手术切除并随后接受 EGFR TKI 治疗可延长生存期
DOI：
10.1186/s12957-017-1252-y
复制
发表时间：
2017-10-16
影响因子：
3.2
通讯作者：
Xu C
中科院分区：
文献类型：
--
作者：
Gui Q;Liu J;Li D;Xu C
背景表皮生长因子受体（EGFR）突变的非小细胞肺癌（NSCLC）伴孤立性脑转移（BM）患者的初始和后续治疗的标准组合尚不清楚。因此，管理选项和无进展生存期（PFS）和总生存期（OS）的EGFR突变的NSCLC患者孤立BM进行了调查的study.MethodsWe回顾性分析了临床数据，从NSCLC患者谁窝藏EGFR突变，谁提出孤立BM在我院2012年和2014年之间的诊断。PFS和OS使用Kaplan-Meier方法进行评估，并使用log-rank tests.ResultsIn总数，36例NSCLC患者孤立BM谁窝藏EGFR突变入组本研究。这些患者的PFS和OS分别为12.4和19.3个月。16例患者接受了脑和肺病变的手术切除术，随后接受了EGFR-TKI治疗，中位OS为28.0个月，显著长于14例接受放疗联合或随后接受EGFR-酪氨酸激酶抑制剂（TKI）治疗的患者的16.4个月和6例接受放疗后接受化疗的患者的15.8个月。各组的中位PFS也显示出相同的趋势（分别为16.1、10.4和9.8个月）。结论接受脑和肺病变手术切除后接受EGFR-TKIs治疗的患者生存期延长，手术联合EGFR-TKIs可作为EGFR突变伴单发BM的NSCLC患者的推荐治疗方法。
BackgroundThe standard combination of initial and subsequent treatments of epidermal growth factor receptor (EGFR)-mutated non-small cell lung cancer (NSCLC) patients with solitary brain metastases (BM) remain unclear. Thus, the management options and the progression-free survival (PFS) and the overall survival (OS) of EGFR-mutated NSCLC patients with solitary BM were investigated in the study.MethodsWe retrospectively reviewed the clinical data from NSCLC patients who harbored EGFR mutations and who presented solitary BM at diagnosis in our institute between 2012 and 2014. PFS and OS were evaluated using Kaplan-Meier methods and compared using log-rank tests.ResultsIn total, 36 NSCLC patients with solitary BM who harbored EGFR mutations were enrolled in this study. The PFS and OS of these patients was 12.4 and 19.3 months, respectively. Sixteen patients underwent surgical resection of brain and lung lesions followed by EGFR-TKIs treatment, and the median OS was 28.0 months, which was significantly longer than 16.4 months of 14 patients received radiotherapy combined with or followed by EGFR-tyrosine kinase inhibitors (TKIs) and 15.8 months of 6 patients received radiotherapy followed by chemotherapy. The median PFS also showed the same trend in each group (16.1, 10.4, and 9.8 months, respectively).ConclusionsThe survival was extended in the patients receiving surgical resection of brain and lung lesions followed by EGFR-TKIs treatment, and surgery combined with EGFR-TKIs could be a recommended treatment for EGFR mutated NSCLC patients with solitary BM.
登录
查看更多内容
影响因子：
5.3
作者：
Park, S. J.;Kim, H. T.;Lee, J. S.
通讯作者：
Lee, J. S.
影响因子：
19.7
作者：
Mujoomdar, Amol;Austin, John H. M.;Raftopoulos, Haralambos
通讯作者：
Raftopoulos, Haralambos
影响因子：
6.2
作者：
Lind, Joline S. W.;Lagerwaard, Frank J.;Senan, Suresh
通讯作者：
Senan, Suresh
影响因子：
3.6
作者：
Zhao, Jing;Chen, Minjiang;Wang, Mengzhao
通讯作者：
Wang, Mengzhao
亚洲晚期非小细胞腺癌组织学肺癌患者 EGFR 突变的前瞻性分子流行病学研究 (PIONEER)。
DOI：
10.1097/jto.0000000000000033
发表时间：
2014-02
期刊：
Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer
影响因子：
--
作者：
Shi Y;Au JS;Thongprasert S;Srinivasan S;Tsai CM;Khoa MT;Heeroma K;Itoh Y;Cornelio G;Yang PC
通讯作者：
Yang PC